Bonus BioGroup says its MesenCure experimental treatment resulted in 94% survival rate of trial subjects and cut hospitalization time in half. Read print story.
By Abigail Klein Leichman | posted 11/25/2021
Bonus BioGroup says its MesenCure experimental treatment resulted in 94% survival rate of trial subjects and cut hospitalization time in half. Read print story.
By Abigail Klein Leichman | posted 11/25/2021